RCEL AVITA Medical, Inc.
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1762303 · Fiscal year ends 12/31
Financial factors as of 2025-09-30 (2025Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY20.6%
TTM net income YoY15.3%
TTM EPS YoY18.8%
Revenue 3-yr CAGR31.4%
Net income 3-yr CAGR—
Margins
Gross margin83.7%
Operating margin-58.1%
Net margin-67.1%
FCF margin-51.3%
EBITDA margin-55.7%
Returns
ROE-1,746.3%
ROA-67.1%
ROIC (approx.)-117.7%
Asset turnover1.00x
Leverage & solvency
Liabilities / assets110.5%
Debt / equity—
Current ratio0.67x
Interest coverage-8.33x
Cash quality & payout
Operating cash flow / net income0.70x
Accruals ratio-20.3%
Payout ratio—
Capex / revenue4.5%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $71.61M | $64.25M |
| Cost of revenue | $12.79M | $9.09M |
| Gross profit | $58.82M | $55.16M |
| R&D expense | $20.84M | $20.36M |
| SG&A expense | $27.37M | $33.20M |
| Operating income | -$42.53M | -$56.59M |
| Interest expense | $5.00M | $5.36M |
| Pretax income | -$48.58M | -$61.79M |
| Income tax | $11,000 | $54,000 |
| Net income | -$48.59M | -$61.84M |
| EBITDA | -$40.19M | -$55.47M |
| EPS (basic) | -1.74 | -2.39 |
| EPS (diluted) | -1.74 | -2.39 |
| Weighted avg. shares (diluted) | 27.86M | 25.88M |
| Banking | ||
| Provision for credit losses | -$10,000 | $23,000 |
| Balance sheet | ||
| Cash & equivalents | $10.24M | $14.05M |
| Short-term investments | $7.94M | $21.84M |
| Receivables | $9.09M | $11.80M |
| Inventory | $6.93M | $7.27M |
| Current assets | $35.49M | $57.00M |
| PP&E, net | $8.63M | $10.02M |
| Intangibles | $5.64M | $5.57M |
| Total assets | $56.39M | $79.71M |
| Current liabilities | $62.68M | $20.16M |
| Short-term debt | $42.98M | $0 |
| Long-term debt | $0 | $42.24M |
| Total debt | $42.98M | $42.24M |
| Total liabilities | $73.04M | $74.97M |
| Shareholders' equity | -$16.65M | $4.50M |
| Net debt | $32.74M | $28.20M |
| Shares outstanding | 30.57M | 26.35M |
| Cash flow statement | ||
| Operating cash flow | -$31.20M | -$48.94M |
| Capital expenditure | $1.00M | $9.17M |
| Free cash flow | -$32.20M | -$58.11M |
| Investing cash flow | $12.45M | $37.36M |
| Financing cash flow | $14.94M | $3.51M |
| Depreciation & amortization | $2.35M | $1.13M |
| Stock-based compensation | $9.52M | $13.50M |
Free plan shows the latest 2 periods; Pro shows all 9 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.